Regulatory timeline
Federal safety actions on COVID-19 vaccines, in order: signals, pauses, recommendations, warnings, label changes, restrictions and withdrawals — with whether each is still current, was superseded, or was a signal later evaluation did not confirm. A preliminary signal is never shown as an established finding.
Topic: All · Myocarditis and pericarditis · Blood clots and thrombosis with thrombocytopenia (TTS) · Stroke · Guillain-Barré syndrome
Agency: FDA · CDC
-
Guillain-Barré syndrome warning added for the Janssen vaccine; ACIP reaffirms its use
Product: Janssen (Johnson & Johnson) COVID-19 vaccine · Population: Adult recipients
What changed: Fact sheets revised to describe an observed increased risk of Guillain-Barré syndrome in the 42 days after vaccination.
FDA revised the Janssen fact sheets to note an observed increased risk of Guillain-Barré syndrome in the 42 days after vaccination; ACIP reviewed the data and concluded benefits outweighed risks.
Superseded by the 2022 restriction and the 2023 revocation of the Janssen authorization.
Later: The Janssen authorization was restricted in 2022 and revoked in 2023.
Thread: janssen gbs
- Warning — Guillain-Barré syndrome warning added for the Janssen vaccine; ACIP reaffirms its use Superseded